2014/2102(DEC) | [ParlTrack]

Changes: 2021/12/18events.docs, events, docs.docs.url, events.type, committees.shadows, 2020/01/19committees, events.docs.url, 2019/07/06events, procedure.dossier_of_the_committee, activities, committees, procedure.subject, docs, links, other, procedure.final.title, commission, procedure.final.url, 2015/11/04activities.docs.celexid, 2015/11/04activities.text, 2015/10/21activities, procedure.final, procedure.stage_reached, 2015/07/25activities.docs, activities.type, 2015/06/04activities.docs.celexid, 2015/06/01activities.docs.celexid, 2015/05/30activities.docs.celexid, 2015/05/15activities.docs.url, 2015/05/08activities.docs.text, 2015/05/01procedure.stage_reached, activities.docs, activities.type, 2015/04/30activities.type, 2015/04/26activities.committees.shadows.group, committees.shadows.name, activities.committees.shadows.mepref, committees.shadows.mepref, activities.committees.shadows, activities.committees.shadows.name, committees.shadows.group, committees.shadows, 2015/04/19activities.docs.text, 2015/04/18activities, 2015/04/17activities.type, 2015/04/15activities.docs, 2015/04/01activities, procedure.stage_reached

View current state | View Changes for this date

Awaiting committee decision

2014/2102(DEC) 2013 discharge: European Medicines Agency (EMA)
Next event: Indicative plenary sitting date, 1st reading/single reading 2015/04/28

Role	Committee	Rapporteur	Shadows
Lead	CONT	CZARNECKI Ryszard (ECR)	ZDECHOVSKÝ Tomáš (EPP), VAUGHAN Derek (S&D), ALIOT Louis (NI), DE JONG Dennis (GUE/NGL), VALLI Marco (EFD)
Opinion	ENVI	LA VIA Giovanni (EPP)

Lead committee dossier: CONT/8/01623

Subjects

8.70.03.03 2013 discharge

Links

Activites

2015/04/28 Indicative plenary sitting date, 1st reading/single reading
2015/03/23 Vote in committee, 1st reading/single reading
2014/10/20 Committee referral announced in Parliament, 1st reading/single reading
2014/07/30 Non-legislative basic document published
- COM(2014)0510 summary
  
  PURPOSE: presentation by the Commission of the consolidated annual accounts of the European Union for the financial year 2013, as part of the 2013 discharge procedure. Analysis of the accounts of the European Medicines Agency (EMEA). CONTENT: this Commission document sets out the consolidated annual accounts of the European Union for the financial year 2013 as prepared on the basis of the information presented by the institutions, organisations and bodies of the EU, in accordance with Article 129 (2) of the Financial Regulation applicable to the EU's General Budget, including the European Medicines Agency (EMEA). The document contains the figures on which the discharge procedure is based. Discharge procedure of the EU agencies: the EU Budget finances a wide range of policies and programmes throughout the EU. In accordance with the priorities set by the European Parliament and the Council in the multi-annual financial framework (MFF), the European Commission carries out specific programmes, activities and projects in the field with the technical support of some specialised agencies. The consolidated annual accounts of the EU provide information on the activities of the institutions, agencies and other bodies of the EU from a budgetary and accrual accounting perspective. The consolidated reports on the implementation of the general budget of the EU include the budget implementation of all Institutions. Agencies do not have a separate budget inside the EU budget; and they are partially financed by a Commission budget subsidy. Each agency is subject to its own discharge procedure. EMEA: in 2013, the tasks and budget of this agency were as follows: description of the Agency's tasks: the European Medicines Agency, which is located in London, was created by Council Regulation (EEC) No 2309/93, which was replaced by Regulation (EC) No 726/2004 of the European Parliament and of the Council and its role is the coordination of the scientific resources made available by the national authorities in order to ensure the evaluation and supervision of medicinal products for human or veterinary use on the basis of a centralised procedure; the Agency's budget for the 2013 financial year: the Agency’s budget for 2013, as presented in the Commission document on the consolidated annual accounts of the European Union, gives the following figures: § Commitment appropriations: - committed : EUR 252 million; - paid : EUR 243 million; - carried over : 0. § Payment appropriations: - committed : EUR 292 million; - paid : EUR 249 million; - carried over : EUR 33 million. See also the final accounts of the EMA.
- DG {'url': 'http://ec.europa.eu/dgs/budget/', 'title': 'Budget'}, GEORGIEVA Kristalina

Documents

Non-legislative basic document published: COM(2014)0510

Amendments	Dossier
21	2014/2102(DEC) 2014/12/12 ENVI 3 amendments... Amendment 1 # Karin KADENBACH Draft opinion Paragraph 2 2. Notes that in 2013, out of the total resources available to the Agency of EUR 251 560 000, 16,3% (EUR 40 937 454) had been EU budget contributions (including an important and essential special contribution for orphan medicines fee reductions of EUR 6 509 360); likes to stress that this amount represents 0.027% of the overall EU budget; Amendment 2 # Julie GIRLING Draft opinion Paragraph 3 a (new) 3a. Welcomes that a new procedure entered into force in 2014 which corrected the former irregular practice, whereby the Agency paid education contributions directly to schools for staff, in contravention of the Staff Regulations; Amendment 3 # Benedek JÁVOR Draft opinion Paragraph 4 4. Reiterates the important role of the Agency in protecting and promoting public and animal health by assessing and supervising medicines for human or veterinary use; welcomes the annual declarations and the policy on the handling of conflict of interests, last updated and endorsed by the Management Board in March 2012, and invites the Agency to further strengthen its policy on the management and handling of conflicts of interests in order to ensure independence and transparency in all work areas of the Agency; source: 544.370 2015/03/06 CONT 18 amendments... Amendment 1 # Proposal for a decision 1 Paragraph 1 1. Grants the Executive Director of the European Medicines Agency discharge in respect of the implementation of the Agency’s budget for the financial year ~~2013 / Postpones its decision on granting the Executive Director of the European Medicines Agency discharge in respect of the implementation of the Agency’s budget for the financial year~~ 2013; Amendment 10 # Tomáš ZDECHOVSKÝ Motion for a resolution Paragraph 7 7. Acknowledges from the Agency that the transparency criteria for partner, patient, healthcare and consumer organisations has been revised during 2014 in order to increase the transparency of funding; notes the adoption of the document with detailed criteria regarding the evaluation of financial information from patients, consumers and healthcare professionals organisations; notes furthermore that this document is used for assessing the organisations’ eligibility to participate in the dialogue with the Agency; recalls that the document also states that the organisations have to declare any conflict of interests at the start of the meetings through which the dialogue is commenced; further calls on the Agency to introduce a list of the patients´ organizations it is working with and to place it on its website, linking it to the funding sources of these organizations in order to enhance transparency; Amendment 11 # Motion for a resolution Paragraph 7 a (new) 7 a. Acknowledges that the Agency complied with the recommendation of the discharge authority to devote a specific part of its Annual Activity Report on the prevention and management of conflict of interests; Amendment 12 # Tomáš ZDECHOVSKÝ Motion for a resolution Paragraph 8 8. Notes that the Agency's Management Board has endorsed ~~the~~a revised ~~the~~ policy on ~~the~~ handling of declarations of interests of members of scientific committees and experts; regrets that the main loopholes, such as distinction between direct and indirect conflicts of interest, prevail, while the Agency takes into account mainly only direct conflict of interest; notes that the electronic declaration of interests form and the procedural guidance were to be finalised during 2014; calls on the Agency to inform the discharge authority on the outcomes as soon as they are available; Amendment 13 # Motion for a resolution Paragraph 8 a (new) 8 a. Notes with satisfaction that this policy entered into force on 30.01.2015; Amendment 14 # Motion for a resolution Paragraph 8 b (new) 8 b. Welcomes that the revised policy includes a better distinction of the declared interest: a person with an executive or leading role in the development of a medicine during a previous employment has a lifetime bar of non-involvement with the concerned company or product. For the majority of declared interests, a three-year cooling-off period is foreseen; Amendment 15 # Benedek JÁVOR Motion for a resolution Paragraph 8 c (new) 8 c. Notes with regret the Agency's understanding of what constitutes commercial confidential information (CCI) is far too broad and includes companies to redact key data about the trial design, methods, and calls on the Agency to properly implement the provisions of the Clinical Trials Regulation (EU) No 536/2014 especially with regard to clinical trial data not to be considered CCI; Amendment 16 # Tomáš ZDECHOVSKÝ Motion for a resolution Paragraph 8 d (new) 8 d. Regrets that the policies on proactive publication of clinical trial data recently adopted by the Agency go against the transparent provisions of the Clinical Trials Regulation endorsed by the European Parliament by allowing companies to redact data based on potential jeopardy of commercial interests; calls on the Agency to report to the discharge Authority on this issue; Amendment 17 # Benedek JÁVOR Motion for a resolution Paragraph 8 e (new) 8 e. Calls on the Agency to publish on its website detailed reports of the scientific advice provided by the Agency to pharmaceutical companies during the drug development and pre-registration process at the time of trial authorization and in any case not later than 12 months after the end of the trial; notes that advice provided by regulators to companies on drug development and pre-registration plans cannot be considered commercially confidential information since there is an overriding public interest in disclosure; Amendment 18 # Zigmantas BALČYTIS Motion for a resolution Paragraph 9 a (new) 9 a. Takes note that the Agency has adopted a set of internal-control standards (ICS) which are intended to guarantee a consistent level of internal control of all business activities throughout the Agency, and define the management rules that all services must follow in their management of resources; Amendment 2 # Tomáš ZDECHOVSKÝ Proposal for a decision 1 Paragraph 1 1. Grants the Executive Director of the European Medicines Agency discharge in respect of the implementation of the Agency’s budget for the financial year ~~2013 / Postpones its decision on granting the Executive Director of the European Medicines Agency discharge in respect of the implementation of the Agency’s budget for the financial year~~ 2013; Amendment 3 # Richard ASHWORTH, Beata GOSIEWSKA, Richard SULÍK Proposal for a decision 1 Paragraph 1 1. ~~Grants the Executive Director of the European Medicines Agency discharge in respect of the implementation of the Agency’s budget for the financial year 2013 /~~ Postpones its decision on granting the Executive Director of the European Medicines Agency discharge in respect of the implementation of the Agency’s budget for the financial year 2013; Amendment 4 # Tomáš ZDECHOVSKÝ Proposal for a decision 2 Paragraph 2 2. Approves the closure of the accounts of the European Medicines Agency for the financial year ~~2013 / Postpones the closure of the accounts of the European Medicines Agency for the financial year~~ 2013; Amendment 5 # Richard ASHWORTH, Beata GOSIEWSKA, Richard SULÍK Proposal for a decision 2 Paragraph 2 2. ~~Approves the closure of the accounts of the European Medicines Agency for the financial year 2013 /~~ Postpones the closure of the accounts of the European Medicines Agency for the financial year 2013; Amendment 6 # Tomáš ZDECHOVSKÝ Motion for a resolution Paragraph 2 – indent 3 – in order to improve its communication with Union citizens, the Agency has recently implemented several initiatives such as publication of strategic documents including summaries for the public, meeting highlights, newsletters or annual reports; notes furthermore in this regard the development of IT communication tools such as ‘Public health communication’ which provides the public with key information on medicines, mainly on their safety; in this regard encourages the Agency to set the pharmacovigilance public hearings; Amendment 7 # Tomáš ZDECHOVSKÝ Motion for a resolution Paragraph 3 a (new) 3 a. Notes that 83% of Agency´s budget comes from the industry fees, representing gradual increase; requires complete transparency about this aspect of budget to avoid any risks for consumers´ rights or Agency´s reputation; Amendment 8 # Tomáš ZDECHOVSKÝ Motion for a resolution Paragraph 6 a (new) 6 a. Notes that the Agency faced some controversy regarding several cases of recruitment procedures in the past; calls on the Agency to always ensure complete transparency and clarification with regard to the recruitment procedures; Amendment 9 # Benedek JÁVOR Motion for a resolution Paragraph 7 7. Acknowledges from the Agency that the transparency criteria for partner, patient, healthcare and consumer organisations has been revised during 2014 in order to increase the transparency of funding; notes the adoption of the document with detailed criteria regarding the evaluation of financial information from patients, consumers and healthcare professionals organisations; notes furthermore that this document is used for assessing the organisations’ eligibility to participate in the dialogue with the Agency; recalls that the document also states that the organisations have to declare any conflict of interests at the start of the meetings through which the dialogue is commenced; notes with regret the reduction of cool-off periods from 5 to 3 years; furthermore, notes with regret that the arbitrary distinction between direct and indirect conflicts of interest has been kept; source: 539.758

Amendments

Dossier

2014/2102(DEC)

2014/12/12 ENVI 3 amendments...

source: 544.370

2015/03/06 CONT 18 amendments...

Amendment 1 #

Proposal for a decision 1
Paragraph 1

1. Grants the Executive Director of the European Medicines Agency discharge in respect of the implementation of the Agency’s budget for the financial year ~~2013 / Postpones its decision on granting the Executive Director of the European Medicines Agency discharge in respect of the implementation of the Agency’s budget for the financial year~~ 2013;

Amendment 10 #

Tomáš ZDECHOVSKÝ

Motion for a resolution
Paragraph 7

7. Acknowledges from the Agency that the transparency criteria for partner, patient, healthcare and consumer organisations has been revised during 2014 in order to increase the transparency of funding; notes the adoption of the document with detailed criteria regarding the evaluation of financial information from patients, consumers and healthcare professionals organisations; notes furthermore that this document is used for assessing the organisations’ eligibility to participate in the dialogue with the Agency; recalls that the document also states that the organisations have to declare any conflict of interests at the start of the meetings through which the dialogue is commenced; further calls on the Agency to introduce a list of the patients´ organizations it is working with and to place it on its website, linking it to the funding sources of these organizations in order to enhance transparency;

Amendment 11 #

Motion for a resolution
Paragraph 7 a (new)

7 a. Acknowledges that the Agency complied with the recommendation of the discharge authority to devote a specific part of its Annual Activity Report on the prevention and management of conflict of interests;

Amendment 12 #

Tomáš ZDECHOVSKÝ

Motion for a resolution
Paragraph 8

8. Notes that the Agency's Management Board has endorsed ~~the~~a revised ~~the~~ policy on ~~the~~ handling of declarations of interests of members of scientific committees and experts; regrets that the main loopholes, such as distinction between direct and indirect conflicts of interest, prevail, while the Agency takes into account mainly only direct conflict of interest; notes that the electronic declaration of interests form and the procedural guidance were to be finalised during 2014; calls on the Agency to inform the discharge authority on the outcomes as soon as they are available;

Amendment 13 #

Motion for a resolution
Paragraph 8 a (new)

8 a. Notes with satisfaction that this policy entered into force on 30.01.2015;

Amendment 14 #

Motion for a resolution
Paragraph 8 b (new)

8 b. Welcomes that the revised policy includes a better distinction of the declared interest: a person with an executive or leading role in the development of a medicine during a previous employment has a lifetime bar of non-involvement with the concerned company or product. For the majority of declared interests, a three-year cooling-off period is foreseen;

Amendment 15 #

Benedek JÁVOR

Motion for a resolution
Paragraph 8 c (new)

8 c. Notes with regret the Agency's understanding of what constitutes commercial confidential information (CCI) is far too broad and includes companies to redact key data about the trial design, methods, and calls on the Agency to properly implement the provisions of the Clinical Trials Regulation (EU) No 536/2014 especially with regard to clinical trial data not to be considered CCI;

Amendment 16 #

Tomáš ZDECHOVSKÝ

Motion for a resolution
Paragraph 8 d (new)

8 d. Regrets that the policies on proactive publication of clinical trial data recently adopted by the Agency go against the transparent provisions of the Clinical Trials Regulation endorsed by the European Parliament by allowing companies to redact data based on potential jeopardy of commercial interests; calls on the Agency to report to the discharge Authority on this issue;

Amendment 17 #

Benedek JÁVOR

Motion for a resolution
Paragraph 8 e (new)

8 e. Calls on the Agency to publish on its website detailed reports of the scientific advice provided by the Agency to pharmaceutical companies during the drug development and pre-registration process at the time of trial authorization and in any case not later than 12 months after the end of the trial; notes that advice provided by regulators to companies on drug development and pre-registration plans cannot be considered commercially confidential information since there is an overriding public interest in disclosure;

Amendment 18 #

Zigmantas BALČYTIS

Motion for a resolution
Paragraph 9 a (new)

9 a. Takes note that the Agency has adopted a set of internal-control standards (ICS) which are intended to guarantee a consistent level of internal control of all business activities throughout the Agency, and define the management rules that all services must follow in their management of resources;

Amendment 2 #

Tomáš ZDECHOVSKÝ

Proposal for a decision 1
Paragraph 1

Amendment 3 #

Richard ASHWORTH, Beata GOSIEWSKA, Richard SULÍK

Proposal for a decision 1
Paragraph 1

1. ~~Grants the Executive Director of the European Medicines Agency discharge in respect of the implementation of the Agency’s budget for the financial year 2013 /~~ Postpones its decision on granting the Executive Director of the European Medicines Agency discharge in respect of the implementation of the Agency’s budget for the financial year 2013;

Amendment 4 #

Tomáš ZDECHOVSKÝ

Proposal for a decision 2
Paragraph 2

2. Approves the closure of the accounts of the European Medicines Agency for the financial year ~~2013 / Postpones the closure of the accounts of the European Medicines Agency for the financial year~~ 2013;

Amendment 5 #

Richard ASHWORTH, Beata GOSIEWSKA, Richard SULÍK

Proposal for a decision 2
Paragraph 2

2. ~~Approves the closure of the accounts of the European Medicines Agency for the financial year 2013 /~~ Postpones the closure of the accounts of the European Medicines Agency for the financial year 2013;

Amendment 6 #

Tomáš ZDECHOVSKÝ

Motion for a resolution
Paragraph 2 – indent 3

– in order to improve its communication with Union citizens, the Agency has recently implemented several initiatives such as publication of strategic documents including summaries for the public, meeting highlights, newsletters or annual reports; notes furthermore in this regard the development of IT communication tools such as ‘Public health communication’ which provides the public with key information on medicines, mainly on their safety; in this regard encourages the Agency to set the pharmacovigilance public hearings;

Amendment 7 #

Tomáš ZDECHOVSKÝ

Motion for a resolution
Paragraph 3 a (new)

3 a. Notes that 83% of Agency´s budget comes from the industry fees, representing gradual increase; requires complete transparency about this aspect of budget to avoid any risks for consumers´ rights or Agency´s reputation;

Amendment 8 #

Tomáš ZDECHOVSKÝ

Motion for a resolution
Paragraph 6 a (new)

6 a. Notes that the Agency faced some controversy regarding several cases of recruitment procedures in the past; calls on the Agency to always ensure complete transparency and clarification with regard to the recruitment procedures;

Amendment 9 #

Benedek JÁVOR

Motion for a resolution
Paragraph 7

7. Acknowledges from the Agency that the transparency criteria for partner, patient, healthcare and consumer organisations has been revised during 2014 in order to increase the transparency of funding; notes the adoption of the document with detailed criteria regarding the evaluation of financial information from patients, consumers and healthcare professionals organisations; notes furthermore that this document is used for assessing the organisations’ eligibility to participate in the dialogue with the Agency; recalls that the document also states that the organisations have to declare any conflict of interests at the start of the meetings through which the dialogue is commenced; notes with regret the reduction of cool-off periods from 5 to 3 years; furthermore, notes with regret that the arbitrary distinction between direct and indirect conflicts of interest has been kept;

source: 539.758

History

(these mark the time of scraping, not the official date of the change)

2015-03-26Show (1) Changes | Timetravel

activities/2

date: 2015-03-23T00:00:00

body: EP

type: Vote in committee, 1st reading/single reading

committees: body: EP shadows: group: EPP name: ZDECHOVSKÝ Tomáš group: S&D name: VAUGHAN Derek group: GUE/NGL name: DE JONG Dennis group: EFD name: VALLI Marco group: NI name: ALIOT Louis responsible: True committee: CONT date: 2014-10-09T00:00:00 committee_full: Budgetary Control rapporteur: group: ECR name: CZARNECKI Ryszard body: EP responsible: False committee: ENVI date: 2014-11-05T00:00:00 committee_full: Environment, Public Health and Food Safety rapporteur: group: EPP name: LA VIA Giovanni

2015-03-25Show (6) Changes | Timetravel

activities/0	date 2014-07-30T00:00:00 docs url: http://www.europarl.europa.eu/registre/docs_autres_institutions/commission_europeenne/com/2014/0510/COM_COM(2014)0510_FR.pdf celexid: CELEX:52014DC0510:EN type: Non-legislative basic document published title: COM(2014)0510 body EC type Non-legislative basic document published commission DG: url: http://ec.europa.eu/dgs/budget/ title: Budget Commissioner: GEORGIEVA Kristalina
activities/0/body	Old EP New EC
activities/0/commission	DG: url: http://ec.europa.eu/dgs/budget/ title: Budget Commissioner: GEORGIEVA Kristalina
activities/0/date	Old 2015-03-23T00:00:00 New 2014-07-30T00:00:00
activities/0/docs	url: http://www.europarl.europa.eu/registre/docs_autres_institutions/commission_europeenne/com/2014/0510/COM_COM(2014)0510_FR.pdf title: COM(2014)0510 type: Non-legislative basic document published celexid: CELEX:52014DC0510:EN
activities/0/type	Old Vote scheduled in committee, 1st reading/single reading New Non-legislative basic document published

2015-03-12Show (1) Changes | Timetravel

activities/0/docs/0/celexid

CELEX:52014DC0510:EN

2015-03-06Show (1) Changes | Timetravel

activities/2/date

Old

2015-03-24T00:00:00

New

2015-03-23T00:00:00

2015-02-19Show (1) Changes | Timetravel

activities/0/docs/0/celexid

CELEX:52014DC0510:EN

2014-12-11Show (2) Changes | Timetravel

activities/0/commission/0	DG url: http://ec.europa.eu/dgs/budget/ title: Budget Commissioner GEORGIEVA Kristalina
other/0	body EC dg url: http://ec.europa.eu/dgs/budget/ title: Budget commissioner GEORGIEVA Kristalina

2014-11-14Show (2) Changes | Timetravel

activities/1/committees/0/shadows/2/mepref	Old 545fbdc8d1d1c57505000000 New 4f1ac952b819f25efd00012c
committees/0/shadows/2/mepref	Old 545fbdc8d1d1c57505000000 New 4f1ac952b819f25efd00012c

2014-11-09Show (7) Changes | Timetravel

activities/0/docs/0/text	PURPOSE: presentation by the Commission of the consolidated annual accounts of the European Union for the financial year 2013, as part of the 2013 discharge procedure. Analysis of the accounts of the European Medicines Agency (EMEA). CONTENT: this Commission document sets out the consolidated annual accounts of the European Union for the financial year 2013 as prepared on the basis of the information presented by the institutions, organisations and bodies of the EU, in accordance with Article 129 (2) of the Financial Regulation applicable to the EU's General Budget, including the European Medicines Agency (EMEA). The document contains the figures on which the discharge procedure is based. Discharge procedure of the EU agencies: the EU Budget finances a wide range of policies and programmes throughout the EU. In accordance with the priorities set by the European Parliament and the Council in the multi-annual financial framework (MFF), the European Commission carries out specific programmes, activities and projects in the field with the technical support of some specialised agencies. The consolidated annual accounts of the EU provide information on the activities of the institutions, agencies and other bodies of the EU from a budgetary and accrual accounting perspective. The consolidated reports on the implementation of the general budget of the EU include the budget implementation of all Institutions. Agencies do not have a separate budget inside the EU budget; and they are partially financed by a Commission budget subsidy. Each agency is subject to its own discharge procedure. EMEA: in 2013, the tasks and budget of this agency were as follows: description of the Agency's tasks: the European Medicines Agency, which is located in London, was created by Council Regulation (EEC) No 2309/93, which was replaced by Regulation (EC) No 726/2004 of the European Parliament and of the Council and its role is the coordination of the scientific resources made available by the national authorities in order to ensure the evaluation and supervision of medicinal products for human or veterinary use on the basis of a centralised procedure; the Agency's budget for the 2013 financial year: the Agency’s budget for 2013, as presented in the Commission document on the consolidated annual accounts of the European Union, gives the following figures: § Commitment appropriations: - committed : EUR 252 million; - paid : EUR 243 million; - carried over : 0. § Payment appropriations: - committed : EUR 292 million; - paid : EUR 249 million; - carried over : EUR 33 million. See also the final accounts of the EMA.
activities/1/committees/0/shadows	group: EPP name: ZDECHOVSKÝ Tomáš group: S&D name: VAUGHAN Derek group: GUE/NGL name: DE JONG Dennis group: EFD name: VALLI Marco group: NI name: ALIOT Louis
activities/1/committees/1/date	2014-11-05T00:00:00
activities/1/committees/1/rapporteur	group: EPP name: LA VIA Giovanni
committees/0/shadows	group: EPP name: ZDECHOVSKÝ Tomáš group: S&D name: VAUGHAN Derek group: GUE/NGL name: DE JONG Dennis group: EFD name: VALLI Marco group: NI name: ALIOT Louis
committees/1/date	2014-11-05T00:00:00
committees/1/rapporteur	group: EPP name: LA VIA Giovanni

2014-10-23Show (5) Changes

activities	date: 2014-07-30T00:00:00 docs: url: http://www.europarl.europa.eu/registre/docs_autres_institutions/commission_europeenne/com/2014/0510/COM_COM(2014)0510_FR.pdf celexid: CELEX:52014DC0510:EN type: Non-legislative basic document published title: COM(2014)0510 type: Non-legislative basic document published body: EC commission: date: 2014-10-20T00:00:00 body: EP type: Committee referral announced in Parliament, 1st reading/single reading committees: body: EP responsible: True committee: CONT date: 2014-10-09T00:00:00 committee_full: Budgetary Control rapporteur: group: ECR name: CZARNECKI Ryszard body: EP responsible: False committee_full: Environment, Public Health and Food Safety committee: ENVI date: 2015-03-24T00:00:00 body: EP type: Vote scheduled in committee, 1st reading/single reading date: 2015-04-28T00:00:00 body: EP type: Indicative plenary sitting date, 1st reading/single reading
committees	body: EP responsible: True committee: CONT date: 2014-10-09T00:00:00 committee_full: Budgetary Control rapporteur: group: ECR name: CZARNECKI Ryszard body: EP responsible: False committee_full: Environment, Public Health and Food Safety committee: ENVI
links
other
procedure	dossier_of_the_committee CONT/8/01623 reference 2014/2102(DEC) title 2013 discharge: European Medicines Agency (EMA) stage_reached Awaiting committee decision type DEC - Discharge procedure subject 8.70.03.03 2013 discharge

Activites

Documents

History

ParlTrack - 2011-2024